Implantation of Patients' Myeloma Cells in SCID Mice
| . | Control Mice . | Patient No. 1 . | Patient No. 2 . | Patient No. 3 . | Patient No. 4 . | Patient No. 5 . |
|---|---|---|---|---|---|---|
| Patient's disease | − | PCL | MM | MM | MM | MM |
| Tumor | + | − | − | − | − | − |
| Human Ig (μg/mL) | <1 | 150 | 8.1 | 10.7 | 8.8 | 11.9 |
| Soluble human IL-6R (ng/mL) | <20 | 78 | 41 | 33 | <20 | <20 |
| Soluble human gp130 (ng/mL) | <5 | 125 | <5 | <5 | <5 | <5 |
| Tumoral infiltration* | +++ | + | + | + | + | + |
| . | Control Mice . | Patient No. 1 . | Patient No. 2 . | Patient No. 3 . | Patient No. 4 . | Patient No. 5 . |
|---|---|---|---|---|---|---|
| Patient's disease | − | PCL | MM | MM | MM | MM |
| Tumor | + | − | − | − | − | − |
| Human Ig (μg/mL) | <1 | 150 | 8.1 | 10.7 | 8.8 | 11.9 |
| Soluble human IL-6R (ng/mL) | <20 | 78 | 41 | 33 | <20 | <20 |
| Soluble human gp130 (ng/mL) | <5 | 125 | <5 | <5 | <5 | <5 |
| Tumoral infiltration* | +++ | + | + | + | + | + |
Freshly explanted myeloma cells (50 × 106) from 1 patient with PCL and 4 with MM were imbedded in 150 μL of soft matrigel together with 3 μg of anti-gp130 MoAb mixture (1.5 μg each), and the gel was implanted surgically IP in SCID mice. These mice were injected IP 2 days before with 100 μg of B-S12 + B-P8 anti-gp130 MoAbs. Then, 50 μg of B-S12 + B-P8 anti-gp130 MoAbs were injected IP every fortnight. Mice either developed tumors (patient no. 1) or were killed at 360 days to look for human myeloma cells in the bone marrow, spleen, blood, liver, pancreas, or mesenteric adipose tissue. The levels of circulating human Ig, sIL-6R, and sgp130 were also assayed. Five mice receiving no human myeloma cells but injected with anti-gp130 MoAbs were used as controls.
Abbreviation: PCL, plasma cell leukemia.
Myeloma cells from the 4 patients with MM were detected in mesenteric adipose tissue.